Dr. Stefan Irion is the Senior Vice President of Research at BlueRock Therapeutics, a leading engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases. He talks about the company’s Parkinson’s disease trial and the challenges of genetically manipulating stem cells. He also discusses his journey from physician to scientist and his personal connection to Parkinson’s disease.
Related News
Press Releases
BlueRock Therapeutics announces publication in Nature of 18-month data from Phase 1 clinical trial for bemdaneprocel, an investigational cell therapy for Parkinson’s disease
April 16, 2025
Press Releases
